Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise.
In the company’s own words · 10-K filed Feb 10, 2026 · SEC EDGAR
Business segments
Q1 2026 · $706.6MThe company’s own SEC segment disclosure.
- Metabolic$237.6M34%
- Oncology$201.2M28%
- Other$93.3M13%
- Central Nervous System$80.2M11%
- Cardiology$56.3M8%
- Antiviral And Anti Infective$38.0M5%
Medpace Holdings, Inc. (MEDP) reported revenue of $707M in Q2 2026 (quarter ended June 30, 2026), up 17% from the same quarter a year earlier. That came with a gross margin of 29% and net income of $121M (17% of revenue). For the full year FY2025, revenue was $2.53B (+20% year on year) and net income $451M. Its largest product in 2026-Q1 was Metabolic at $238M, 34% of the disclosed total, just ahead of Oncology at 28%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #3 of 29 by Smart Score